Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.
March 2021
A wave of approvals and a rapidly evolving treatment landscape could make the next decade a watershed period in breast cancer care.
The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.
Advertisement
Advertisement
Trending on OncLive
1
Dr Mesa on the FDA Approval of Ropeginterferon Alfa-2b for Essential Thrombocythemia
2
Zanidatamab Plus Chemotherapy Improves OS at Second Interim Analysis of HERIZON-GEA-01 in First-Line HER2+ GEA
3
Savolitinib Plus Osimertinib Improves First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC
4
TTFields Add a New Dimension to the Changing Pancreatic Cancer Treatment Paradigm
5